- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- lufepirsen high dose, Vehicle, lufepirsen low dose
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Venous Leg Ulcers
- Interventions
- Nexagon® Low Dose, Nexagon® High Dose, Nexagon® Vehicle
- Drug
- Lead sponsor
- OcuNexus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 15 more
- Conditions
- Venous Ulcer
- Interventions
- Nexagon®, Nexagon® vehicle
- Drug
- Lead sponsor
- OcuNexus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- San Francisco, California • Stockton, California • Erie, Pennsylvania + 1 more
- Conditions
- Corneal Persistent Epithelial Defect
- Interventions
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Open-label Nexagon® (lufepirsen)
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diabetic Foot Ulcers
- Interventions
- Nexagon® Low Dose, Nexagon® Medium Dose, Nexagon® High Dose, Nexagon® vehicle
- Drug
- Lead sponsor
- OcuNexus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 6 more